Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 13/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6017164 | 0.74 | ALDH1A1 (0.41) | FDPSLMNAKDM4EMMP2THRB | |
| SCHEMBL10018539 | 0.74 | FDPS (0.36) | FDPSLAP3LPAR3KDM4EMMP2 | |
| SCHEMBL9013448 | 0.74 | LPAR3 (0.41) | FDPSLPAR3LPAR2 | |
| SCHEMBL9643758 | 0.74 | GRM4 (0.50) | FDPSGGPS1LPAR3LPAR2 | |
| SCHEMBL7961072 | 0.72 | LPAR3 (0.39) | FDPSLMNALAP3LPAR3KDM4E | |
| SCHEMBL11322414 | 0.72 | GRM4 (0.37) | FDPSLMNALAP3LPAR3KDM4E | |
| SCHEMBL2780862 | 0.72 | FDPS (0.59) | FDPSGGPS1LPAR3 | |
| SCHEMBL27469645 | 0.71 | LMNA (0.45) | FDPSLMNALAP3GGPS1KDM4E | |
| SCHEMBL3365741 | 0.71 | — | — | |
| SCHEMBL23178029 | 0.70 | PGK1 (0.36) | FDPSLMNALAP3LPAR3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131908-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | BANK OF AMERICA, N.A. | 2015-03-19 | — | — | US | disclosed |
| US-8927513-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8921439-B2 | Monohydroxy cyclic phosphonate substantially free of polyhydroxy phosphonate, process for making same and flame retardant flexible polyurethane foam obtained therefrom | ICL-IP AMERICA INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2619213-B1 | MONOHYDROXY CYCLIC PHOSPHONATE SUBSTANTIALLY FREE OF POLYHYDOXY PHOSPHONATE, PROCESS FOR MAKING SAME AND FLAME RETARDANT FLEXIBLE POLYURETHANE FOAM OBTAINED THEREFROM | ICL IP AMERICA INC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20130237623-A1 | MONOHYDROXY CYCLIC PHOSPHONATE SUBSTANTIALLY FREE OF POLYHYDROXY PHOSPHONATE, PROCESS FOR MAKING SAME AND FLAME RETARDANT FLEXIBLE POLYURETHANE FOAM OBTAINED THEREFROM | ICL-IP AMERICA INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8357689-B2 | Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type I and II diabetes mellitus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-8211923-B2 | Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type I and II diabetes mellitus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-03 | — | — | US | disclosed |
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011005860-A2 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100210594-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210595-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-2185571-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | Boehringer Ingelheim International GmbH (DE) | 2010-05-19 | — | — | EP | disclosed |
| EP-2185572-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | Boehringer Ingelheim International GmbH (DE) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016119-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016118-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | FDPS 996/4885LMNA 2073/4885LAP3 2749/4885 |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | FDPS 1012/4885LMNA 2072/4885LAP3 2699/4885 |
| US-20100210595-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | G6PC1, PYGL, PPP1CA | FDPS 2047/4885LMNA 732/4885LAP3 1480/4885 |
| US-10131908-B2 | 5′ phosphate mimics | NSUN2, RNGTT, RNMT | FDPS 1072/4885LMNA 2063/4885LAP3 2794/4885 |
| US-20100210594-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | G6PC1, PYGL, PPP1CA | FDPS 2047/4885LMNA 732/4885LAP3 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.